Published • loading... • Updated
Investigating the feasibility of gene therapy for stereocilin-related hearing loss
Summary by RNID
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Investigating the feasibility of gene therapy for stereocilin-related hearing loss
In this project, Professor Els Henckaerts at KU Leuven, Belgium, is testing gene therapy as a method to treat hearing loss caused by mutations in the ‘stereocilin’ gene. Project start date: March 2026Project end date: February 2028 About the project One of the most common genetic causes of childhood hearing loss is a mutation in the stereocilin gene, which leads to a type of hearing loss called ‘DFNB16’. Current care for this condition involves …
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
